Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

The Medicines Company and Alnylam to develop therapeutics for hypercholesterolemia

Feb. 5, 2013

Lyxumia approved in E.U. as first once-daily prandial GLP-1 receptor agonist

Feb. 4, 2013

FDA approves Ravicti for urea cycle disorders

Feb. 4, 2013

Glucose lowered equally with mitoglitazone and pioglitazone in diabetes trial

Feb. 1, 2013

Diamyd Medical to conduct new study of diabetes vaccine

Jan. 31, 2013

Peptide drug shows promise for skeletal dysplasia diseases related to FGFR3 gene mutations

Jan. 31, 2013

FDA approves Kynamro for homozygous familial hypercholesterolemia

Jan. 30, 2013

Delay to topline results from first pivotal study of Androxal

Jan. 29, 2013

Chinese researchers disclose new SGLT2 inhibitors

Jan. 29, 2013

Merck KGaA designs novel FSH receptor agonists

Jan. 29, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...